Wednesday, August 26, 2026

Abaxx Exchange Posts Record Trading Month as It Fights Off Viceroy Short-Seller Report

Abaxx Exchange logged its best trading month on record in June 2026, even as Viceroy Research published a short-and-distort report attacking parent company Abaxx Technologies. Abaxx hired law firm Paul Weiss to investigate the claims and asked regulators MAS and CIRO to review the matter, with the CIRO request targeting Viceroy's own trading activity.

LM Salvado
LM Salvado

July 12, 2026

Abaxx Exchange Posts Record Trading Month as It Fights Off Viceroy Short-Seller Report
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Abaxx Exchange posted its best trading month on record in June 2026, days after short-seller Viceroy Research published a report accusing parent company Abaxx Technologies of wrongdoing.1 The volume spike gives Abaxx an operational counterpoint to the allegations.

Viceroy's report used a short-and-distort strategy, publishing negative claims about Abaxx while the firm holds a short position.2 Abaxx has publicly rejected the findings, calling the report misinformation.1

Abaxx retained law firm Paul Weiss to investigate the allegations.1 The company also engaged two regulators directly: Singapore's Monetary Authority (MAS) and Canada's Investment Regulatory Organization (CIRO).1 The CIRO outreach goes further than a standard rebuttal. Abaxx asked the regulator to examine Viceroy's own trading activity around the report's release, turning the short-seller's tactics into the subject of scrutiny.1

For traders, the June volume record is the more concrete data point. A short-and-distort report is designed to pressure a stock price by amplifying negative claims. Record trading activity in the same window suggests market participants kept transacting on Abaxx Exchange rather than pulling back, even as headline risk around the parent company escalated.1

The dispute now runs on two tracks. Paul Weiss's investigation and the regulatory reviews at MAS and CIRO will determine whether Viceroy's allegations hold up.1 Meanwhile, Abaxx Exchange's trading desk has already delivered its own answer in the form of record June volumes, an outcome that runs counter to the market disruption a short-and-distort campaign typically aims to produce.1

Sentiment around the situation remains mixed but has been improving, reflecting a market still weighing unresolved regulatory questions against the exchange's demonstrated trading strength.12

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· June 22, 2026
    Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals
  2. [2]Press releaseGlobeNewswire· June 30, 2026
    Raytech Holding Limited Announces Closing of Approximately $6.2 Million Registered Direct Offering of its Ordinary Shares

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com